Sex hormones, hormonal interventions, and gastric cancer risk: A meta-analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 1, 2012, Pages 20-38

  Camargo, M Constanza ^a   Goto, Yasuyuki ^b   Zabaleta, Jovanny ^c   Morgan, Douglas R ^d   Correa, Pelayo ^e   Rabkin, Charles S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

ADJUVANT THERAPY; AGE; BIRTH; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; DRUG EXPOSURE; ESTROGEN THERAPY; FEMALE; FEMALE FERTILITY; FEMALE GENITAL SYSTEM FUNCTION; HUMAN; MENARCHE; MENOPAUSE; META ANALYSIS; ORAL CONTRACEPTION; PARITY; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; STOMACH CANCER; SYSTEMATIC REVIEW;

ESTROGEN REPLACEMENT THERAPY; FEMALE; GONADAL STEROID HORMONES; HUMANS; REPRODUCTIVE HISTORY; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84855481385     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0834     Document Type: Review

References (105)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Griffith GW. The sex ratio in gastric cancer and hypothetical considerations relative to aetiology. Br J Cancer 1968;22:163-72.
3. Sipponen P, Correa P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer 2002;5:213-9. (Pubitemid 36605884)
4. Lindblad M, Rodríguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 2005;16:285-94. (Pubitemid 40897847)
5. Freedman ND, Derakhshan MH, Abnet CC, Schatzkin A, Hollenbeck AR, McColl KE. Male predominance of upper gastrointestinal adenocarcinoma cannot be explained by differences in tobacco smoking in men versus women. Eur J Cancer 2010;46:2473-8.
6. Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer 2008;44:2397-403.
7. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001;(1):CD000486.
8. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937-47. (Pubitemid 37510624)
9. Chandanos E, Lindblad M, Jia C, Rubio CA, Ye W, Lagergren J. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer 2006;95:118-22. (Pubitemid 43980565)
10. Mellemkjaer L, Friis S, Olsen JH, Scélo G, Hemminki K, Tracey E, et al. Risk of second cancer amongwomen with breast cancer. Int J Cancer 2006;118:2285-92.
11. Duell EJ, Travier N, Lujan-Barroso L, Boutron-Ruault MC, Clavel-Chapelon F, Palli D, et al. Menstrual and reproductive factors, exogenous hormone use, and gastric cancer risk in a cohort of women from the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 2010;172:1384-93.
12. Bradburn MJUpdated and New Commands for Meta-Analysis in STATA. 2004. Cancer Research UK Medical Statistics Group. Oxford: Centre for Statistics in Medicine. [cited 20 May 2011]. Available from: http://www.medepi.net/meta/ software/Bradburn-metan-updates.pdf.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. (Pubitemid 34746062)
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
16. Galbraith RF. Graphical display of estimates having differing standard errors. Technometrics 1988;30:271-81. (Pubitemid 20649623)
17. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354-62. (Pubitemid 43329250)
18. Finley C, Gregg EW, Solomon LJ, Gay E. Disparities in hormone replacement therapy use by socioeconomic status in a primary care population. J Community Health 2001;26:39-50. (Pubitemid 33638551)
19. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. (Pubitemid 27387172)
21. Sterne JAC, editor. Meta-analysis in Stata: an updated collection from the Stata Journal 2009. Stata Press, USA.
22. Miller AB, Barclay TH, Choi NW, Grace MG, Wall C, Plante M, et al. A study of cancer, parity and age at first pregnancy. J Chronic Dis 1980;33:595-605. (Pubitemid 10003337)
23. Plesko I, Preston-Martin S, Day NE, Tzonou A, Dimitrova E, Somogyi J. Parity and cancer risk in Slovakia. Int J Cancer 1985;36:529-33. (Pubitemid 16233509)
24. Tsukuma H, Fujimoto I, Furukawa H, Iwanaga T, Okuda S, Tatsuta M, et al. [A case-control study of stomach cancer in young females, with special reference to the effects of pregnancy and delivery]. [Article in Japanese] Gan No Rinsho 1989;35:35-40.
25. La Vecchia C, Negri E, Franceschi S, Parazzini F. Long-term impact of reproductive factors on cancer risk. Int J Cancer 1993;53:215-9. (Pubitemid 23042868)
26. La Vecchia C, D'Avanzo B, Franceschi S, Negri E, Parazzini F, Decarli A. Menstrual and reproductive factors and gastric-cancer risk in women. Int J Cancer 1994;59:761-4.
27. Palli D, Cipriani F, Decarli A, Galli M, Saieva C, Fraumeni JF Jr, et al. Reproductive history and gastric cancer among post-menopausal women. Int J Cancer 1994;56:812-5. (Pubitemid 24102745)
28. Kvåle G, Heuch I, Nilssen S. Parity in relation to mortality and cancer incidence: a prospective study of Norwegian women. Int J Epidemiol 1994;23:691-9. (Pubitemid 24260367)
29. Heuch I, Kvåle G. Menstrual and reproductive factors and risk of gastric cancer: a Norwegian cohort study. Cancer Causes Control 2000;11:869-74.
30. Inoue M, Ito LS, Tajima K, Yamamura Y, Kodera Y, Takezaki T, et al. Height, weight, menstrual and reproductive factors and risk of gastric cancer among Japanese postmenopausal women: analysis by subsite and histologic subtype. Int J Cancer 2002;97:833-8. (Pubitemid 34106341)
31. Kaneko S, Tamakoshi A, Ohno Y, Mizoue T, Yoshimura T JACC Study Group. Menstrual and reproductive factors and the mortality risk of gastric cancer in Japanese menopausal females. Cancer Causes Control 2003;14:53-9. (Pubitemid 36403269)
32. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003;105:408-12. (Pubitemid 36575452)
33. Heuch I, Kvåle G. Does breastfeeding affect the risk of gastric cancer? Int J Cancer 2003;106:982-3. (Pubitemid 37071682)
34. Lindblad M, García Rodríguez LA, Chandanos E, Lagergren J. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer 2006;94:136-41. (Pubitemid 43088553)
35. Frise S, Kreiger N, Gallinger S, Tomlinson G, Cotterchio M. Menstrual and reproductive risk factors and risk for gastric adenocarcinoma in women: findings from the Canadian national enhanced cancer surveillance system. Ann Epidemiol 2006;16:908-16. (Pubitemid 44873090)
36. Freedman ND, Chow WH, Gao YT, Shu XO, Ji BT, Yang G, et al. Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women. Gut 2007;56:1671-7. (Pubitemid 350206291)
37. Sakauchi F. Japan Collaborative Cohort Study for Evaluation of Cancer. Reproductive history and health screening for women and mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC). Asian Pac J Cancer Prev 2007;8 Suppl:129-34.
38. Persson C, Inoue M, Sasazuki S, Kurahashi N, Iwasaki M, Ye W, et al. Female reproductive factors and the risk of gastric cancer in a large-scale population-based cohort study in Japan (JPHC study). Eur J Cancer Prev 2008;17:345-53.
39. Bahmanyar S, Lambe M, Zendehdel K, Nyrén O, Boffetta P, Ye W. Parity and risk of stomach cancer by sub-site: a national Swedish study. Br J Cancer 2008;98:1295-300. (Pubitemid 351481669)
40. Dorjgochoo T, Shu XO, Li HL, Qian HZ, Yang G, Cai H, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer 2009;124:2442-9.
41. Freedman ND, Lacey JV Jr, Hollenbeck AR, Leitzmann MF, Schatzkin A, Abnet CC. The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort. Cancer 2010;116:1572-81.
42. Chung HW, Noh SH, Lim JB. Analysis of demographic characteristics in 3242 young age gastric cancer patients in Korea. World J Gastroenterol 2010;16:256-63.
43. Chang CC, Chen CC, Chiu HF, Yang CY. Higher parity associated with higher risk of death from gastric cancer. World J Gastroenterol 2011;17:784-8.
44. Green J, Czanner G, Reeves G, Watson J, Wise L, Roddam A, et al. Menopausal hormone therapy and risk of gastrointestinal cancer: Nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer 2011 Jun 13.
45. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83:1013-7.
46. Andersson M, Jensen MB, Engholm G, Henrik Storm H. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. Acta Oncol 2008;47:755-64. (Pubitemid 351878439)
47. Ribeiro G, Swindell R. The Christie hospital adjuvant tamoxifen trial-status at 10 years. Br J Cancer 1988;57:601-3.
48. Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen trial. J Natl Cancer Inst Monogr 1992;11:121-5.
49. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37. (Pubitemid 24111008)
50. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42. (Pubitemid 26374506)
51. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, et al. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J Clin Oncol 1991;9:1740-8.
52. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87:645-51.
53. Curtis RE, Boice JD Jr, Shriner DA, Hankey BF, Fraumeni JF Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996;88:832-4. (Pubitemid 26187392)
54. NewcombPA, Solomon C, White E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat 1999;53:271-7. (Pubitemid 29209896)
55. Rydén S, Fernö M, Möller T, Aspegren K, Bergljung L, Killander D, et al. Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol 1992;31:271-4.
56. Cummings FJ, Gray R, Tormey DC, Davis TE, Volk H, Harris J, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol 1993;11:29-35. (Pubitemid 23059971)
57. Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 1994;12:2078-85. (Pubitemid 24356024)
58. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24. (Pubitemid 35257944)
59. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62. (Pubitemid 41672231)
60. Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007;99:727-37. (Pubitemid 47073533)
61. Matsuyama Y, Tominaga T, Nomura Y, Koyama H, Kimura M, Sano M, et al. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol 2000;11:1537-43. (Pubitemid 32104751)
62. Ursic-Vrscaj M, Kovacic J, Bebar S, Djurisic A, Fras PA, Robic V. Endometrial and other primary cancers after tamoxifen treatment of breast cancer-results of retrospective cohort study. Eur J Obstet Gynecol Reprod Biol 2001;95:105-10. (Pubitemid 32208679)
63. Fowble B, Hanlon A, Freedman G, Nicolaou N, Anderson P. Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys 2001;51:679-90.
64. Romieu I, Berlin JA, Colditz G. Oral contraceptives and breast cancer. Review and meta-analysis. Cancer 1990;66:2253-63.
65. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 2006;81:1290-302. (Pubitemid 44484967)
66. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18. (Pubitemid 28536137)
67. Sheh A, Ge Z, Parry NM, Muthupalani S, Rager JE, Raczynski AR, et al. 17(lowercase beta)-estradiol and tamoxifen prevent gastric cancer by modulating leukocyte recruitment and oncogenic pathways in Helicobacter pylori-infected INS-GAS male mice. Cancer Prev Res (Phila) 2011;4:1426-35.
68. IARC Monographs on the evaluation of carcinogenic risks to humans, Schistosomes, liver flukes and Helicobacter pylori. Lyon, France: IARC Press 1994;61:218-20.
69. Goodman KJ, Correa P, Tenganá Aux HJ, Ramírez H, DeLany JP, Guerrero Pepinosa O, et al. Helicobacter pylori infection in the Colombian Andes: a population-based study of transmission pathways. Am J Epidemiol 1996;144:290-9. (Pubitemid 26313506)
70. Replogle ML, Glaser SL, Hiatt RA, Parsonnet J. Biologic sex as a risk factor for Helicobacter pylori infection in healthy young adults. Am J Epidemiol 1995;142:856-63.
71. de Martel C, Parsonnet J. Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys. Dig Dis Sci 2006;51:2292-301.
72. Klein PD, Gilman RH, Leon-Barua R, Diaz F, Smith EO, Graham DY. The epidemiology of Helicobacter pylori in Peruvian children between 6 and 30 months of age. Am J Gastroenterol 1994;89:2196-200. (Pubitemid 24363669)
73. Kikuchi S, Ohgihara A, Hasegawa A, Miki K, Kaneko E, Mizukoshi H. Seroconversion and seroreversion of Helicobacter pylori antibodies over a 9-year period and related factors in Japanese adults. Helicobacter 2004;9:335-41. (Pubitemid 38988334)
74. Fawcett JP, Barbezat GO, Poulton R, Milne BJ, Xia HH, Talley NJ. Helicobacter pylori serology in a birth cohort of New Zealanders from age 11 to 26. World J Gastroenterol 2005;11:3273-6. (Pubitemid 40973899)
75. Ashorn M, Mäki M, Hällström M, Uhari M, Akerblom HK, Viikari J, et al. Helicobacter pylori infection in Finnish children and adolescents. A serologic cross-sectional and follow-up study. Scand J Gastroenterol 1995;30:876-9.
76. Rehnberg-Laiho L, Rautelin H, Valle M, Kosunen TU. Persisting Helicobacter antibodies in Finnish children and adolescents between two and twenty years of age. Pediatr Infect Dis J 1998;17:796-9. (Pubitemid 28475547)
77. Rosenstock S, Jørgensen T, Andersen L, Bonnevie O. Seroconversion and seroreversion in IgG antibodies to Helicobacter pylori: a serology based prospective cohort study. J Epidemiol Community Health 2000;54:444-50. (Pubitemid 30312521)
78. Hosoda K, Shimomura H, Hayashi S, Yokota K, Oguma K, Hirai Y. Anabolic utilization of steroid hormones in Helicobacter pylori. FEMS Microbiol Lett 2009;297:173-9.
79. Shimomura H, Hosoda K, Hayashi S, Yokota K, Oguma K, Hirai Y. Steroids mediate resistance to the bactericidal effect of phosphatidylcholines against Helicobacter pylori. FEMS Microbiol Lett 2009;301:84-94.
80. Wunder C, Churin Y, Winau F, Warnecke D, Vieth M, Lindner B, et al. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori. Nat Med 2006;12:1030-8. (Pubitemid 44353384)
81. Hosoda K, Shimomura H, Hayashi S, Yokota K, Hirai Y. Steroid hormones as bactericidal agents to Helicobacter pylori. FEMS Microbiol Lett 2011;318:68-75.
82. Ohtani M, García A, Rogers AB, Ge Z, Taylor NS, Xu S, et al. Protective role of 17 beta -estradiol against the development of Helicobacter pylori-induced gastric cancer in INS-GAS mice. Carcinogenesis 2007;28:2597-604. (Pubitemid 350238963)
83. Ohtani M, Ge Z, García A, Rogers AB, Muthupalani S, Taylor NS, et al. 17{beta}-Estradiol suppresses Helicobacter pylori-induced gastric pathology in male hypergastrinemic INS-GAS mice. Carcinogenesis 2011;32:1244-50.
84. Furukawa H, Iwanaga T, Koyama H, Taniguchi H. Effect of sex hormones on the experimental induction of cancer in rat stomach-a preliminary study. Digestion 1982;23:151-5. (Pubitemid 12123957)
85. Tokunaga A, Kojima N, Andoh T, Matsukura N, Yoshiyasu M, Tanaka N, et al. Hormone receptors in gastric cancer. Eur J Cancer Clin Oncol 1983;19:687-9. (Pubitemid 13100379)
86. Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, et al. Estrogen receptor beta is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol 2002;128:319-24. (Pubitemid 34569353)
87. Zhao YF, Zhang YG, Tian XX, Juan Du, Jie Zheng. Aberrant methylation of multiple genes in gastric carcinomas. Int J Surg Pathol 2007;15:242-51.
88. Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 2003;4:721-32. (Pubitemid 37082187)
89. Pricci M, Linsalata M, Russo F, Messa C, Amati L, Caradonna L, et al. Effects of 17beta-estradiol administration on apoptosis and polyamine content in AGS cell line. Anticancer Res 2001;21:3215-20. (Pubitemid 34224220)
90. Yeretssian G, Doiron K, Shao W, Leavitt BR, Hayden MR, Nicholson DW, et al. Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection. Proc Natl Acad Sci U S A 2009;106:9016-20.
91. Nylander-Koski O, Kiviluoto T, Puolakkainen P, Kivilaakso E, Mustonen H. The effect of nitric oxide, growth factors, and estrogen on gastric cell migration. J Surg Res 2007;143:230-7. (Pubitemid 350101563)
92. Ko KP, Park SK, Park B, Yang JJ, Cho LY, Kang C, et al. Isoflavones from phytoestrogens and gastric cancer risk: a nested case-control study within the Korean Multicenter Cancer Cohort. Cancer Epidemiol Biomarkers Prev 2010;19:1292-300.
93. Freedman ND, Ahn J, Hou L, Lissowska J, Zatonski W, Yeager M, et al. Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer. Carcinogenesis 2009;30:71-7.
94. Lindblad M, Ye W, Rubio C, Lagergren J. Estrogen and risk of gastric cancer: a protective effect in a nationwide cohort study of patients with prostate cancer in Sweden. Cancer Epidemiol Biomarkers Prev 2004;13:2203-7. (Pubitemid 40054318)
95. Cardenas VM, Graham DY. Smoking and Helicobacter pylori infection in a sample of U.S. adults. Epidemiology 2005;16:586-90. (Pubitemid 40847849)
96. Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006;119:217-24. (Pubitemid 43255059)
97. IARC Monographs on the evaluation of carcinogenic risks to humans, tobacco smoke and involuntary smoking. Lyon, France; IARC Press 2004;83:557-613.
98. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009;137:824-33.
99. Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer 2011;105:38-43.
100. Lunet N, Valbuena C, Vieira AL, Lopes C, Lopes C, David L, et al. Fruit and vegetable consumption and gastric cancer by location and histological type: case-control and meta-analysis. Eur J Cancer Prev 2007;16:312-27. (Pubitemid 47165297)
101. Baker AH, Wardle J. Sex differences in fruit and vegetable intake in older adults. Appetite 2003;40:269-75. (Pubitemid 36687825)
102. Schätzer M, Rust P, Elmadfa I. Fruit and vegetable intake in Austrian adults: intake frequency, serving sizes, reasons for and barriers to consumption, and potential for increasing consumption. Public Health Nutr 2010;13:480-7.
103. Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Medical Research Methodology 2002;2. Available from: http://www.biomedcentral.com/1471-2288/2/3.
104. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-75. (Pubitemid 38594143)
105. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975;2:58-60.